Stockwinners Market Radar for August 10, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT CarParts.com CEO sells 116.2K shares of common stock - In a regulatory filing, CarParts.com disclosed that its CEO Lev Peker sold 116.2K shares of common stock on August 6th in a total transaction size of $2.3M, reducing his stake by about 10%.

20:01 EDT Lockheed Martin completes construction of Palmdale, CA facility - The company states: "Lockheed Martin has completed construction of an advanced manufacturing facility at its Palmdale, California, campus and headquarters to the Skunk Works. Lockheed Martin's Advanced Manufacturing Facility at the Skunk Works in Palmdale, California, merges the power of human and machine - manufacturing artisans will work with digital tools to execute operations with maximum efficiency. Manufacturing and office space will accommodate 450 employees. This is one of four transformational manufacturing facilities Lockheed Martin is opening in the U.S. this year.The 215,000 square foot intelligent, flexible factory has digital foundations to incorporate smart manufacturing components, embrace the Internet of Things and deliver cutting edge solutions rapidly and affordably to support the United States and its allies. This is one of four transformational manufacturing facilities Lockheed Martin is opening in the U.S. this year. In addition to manufacturing, the facility includes office and break spaces to accommodate more than 450 employees."

18:12 EDT Nucor CEO: We're poised to rebuild the country's crumbling infrastructure - In an interview on CNBC's Mad money, Leon Topalian said Nucor's stock should be trading at a much higher multiple as it's a growth company. "We're going to have to increase output to meet demand," he noted. According to Topalian, the tariffs implemented in 2018 are not long-term and he is not concerned about them.

17:52 EDT Coinbase says goal is to bring 1B people into the cryptoeconomy - Says Q2 illustrated the volatility anticipated in these still-early days in the cryptoeconomy. Says as volatility and crypto asset prices are highly correlated with trading revenue, the crypto market environment heavily influenced Q2 results. Says goal is to bring 1B people into the cryptoeconomy. Says launched the beta of Coinbase Prime. Says regulatory conversations are expanding and fully supports smart regulations that promote innovation. Says will work to propose frameworks that regulators should consider as we continue to encourage smart regulations. Comments taken from Q2 earnings conference call.

17:46 EDT Pan American Silver raises dividend to 10c from 7c - The Board of Directors has approved an increase in the cash dividend from 7c to 10c per common share, or approximately $21.0M in aggregate cash dividends, payable on or about September 3 to holders of record of Pan American's common shares as of the close on August 23.

17:24 EDT General Dynamics to compete for each order on $744.22M Army contract - Sierra Nevada and General Dynamics will compete for each order of the $744.22M contract for the Next Generation Load Device-Medium. Bids were solicited via the internet with five received. Work locations and funding will be determined with each order, with an estimated completion date of August 8, 2031. U.S. Army Contracting Command is the contracting activity.

17:01 EDT Mesa Air reports July block hours up 92.1% - Mesa Air reported Mesa Airlines' operating performance for July 2021. Mesa Airlines reported 32,843 block hours in July 2021, a 92.1 percent increase from July 2020 as a result of increased summer flying and the relaxation of certain COVID restrictions. The Company also reported a controllable completion factor of 98.72 percent and 99.90 percent for its American and United operations, respectively.

16:56 EDT Live Oak Bancshares CAO sells 15,125 common shares - In a regulatory filing, Live Oak Bancshares chief accounting officer John Sutherland disclosed the sale of 15,125 common shares of the company on August 6 at a price of $61.5355 per share.

16:47 EDT Riot Blockchain reports July production 444 BTC, up 771% from last year - Riot Blockchain announces its July production and operations updates, including its unaudited Bitcoin production for July 2021 and its miner shipping/deployment status. In July 2021, Riot produced 444 BTC, an increase of approximately 771% over its July 2020 production of 51 BTC. Year to date through July, the Company produced a total of 1,610 BTC, an increase of approximately 188% over its BTC production during the same 2020 period of 559 BTC. As of July 31 Riot held approximately 2,687 BTC, all of which were produced by its self-mining operations. Riot plans to continue providing monthly operational updates and unaudited production results through the end of 2021. These updates are intended to keep shareholders informed of Riot's mining production as it continues to deploy its expanding miner fleet.

16:43 EDT WW drops 20% to $25.60 after Q2 results, FY21 guidance miss estimates

16:37 EDT Vail Resorts says Kirsten Lynch to be appointed CEO, board member - Vail Resorts (MTN) announced that Kirsten Lynch, the company's chief marketing officer, will be appointed CEO and elected to the company's board of directors, effective November 1. At that time, Rob Katz, the company's current CEO, will be appointed executive chairperson of the board and remain fully active and engaged in Vail Resorts' key strategic decisions and priorities. Additionally, at that time, Ryan Bennett, currently vice president of marketing, lift revenue, will be named chief marketing officer of Vail Resorts. Lynch joined Vail Resorts in 2011 as chief marketing officer and previously held senior leadership positions at PepsiCo (PEP) and Kraft Foods.

16:35 EDT Jamf Holding has identified an immaterial error related to commissions - Jamf has recently identified an immaterial error related to certain commissions that were incorrectly capitalized instead of being expensed in its prior period financial statements and will revise its previously issued consolidated financial statements for fiscal years 2018, 2019, 2020, quarters of 2019 and 2020, and the first quarter of 2021 in subsequent filings. Jamf determined that the error had no impact on key business metrics, including revenue, ARR, dollar-based net retention, operating cash flow and unlevered free cash flow for the relevant periods. Jamf currently estimates that the error will result in an expense adjustment of approximately 1% or less of total GAAP expenses in any of the relevant periods. Jamf does not believe the error will have a material impact on future period operating expense rates. Jamf expects to correct the immaterial error in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Given the timing of the error being identified, Jamf's second quarter 2021 financial results are preliminary subject to the completion of the audit process. Jamf plans to provide its final financial results for the quarter ended June 30, 2021 and file the related Quarterly Report on Form 10-Q as soon as practicable.

16:32 EDT Kaman awarded $43M programmable fuze order - Kaman announced that it received an order under Option 16 of its Joint Programmable Fuze contract with the U.S. Air Force. This order has an expected value of approximately $43M for the procurement of JPFs for foreign militaries.

16:22 EDT Beyond Air sees securing CE Mark in EU around end of CY21 for LungFit PH - For LungFit PRO, plans on initiating a pivotal trial for patients hospitalized with viral lung infections, either for acute viral pneumonia or bronchiolitis, in the fourth quarter of calendar year 2022. For LungFit GO, expects to report interim data for the at-home NTM lung infection pilot study at a medical or scientific conference in Fall 2021 with the trial completing in the first half of calendar year 2022.

16:17 EDT Braemar Hotels & Resorts sees July portfolio occupancy of 69.6% - Braemar Hotels & Resorts reported preliminary portfolio occupancy of 69.6% for the month of July with an average daily rate, or ADR, of approximately $387 resulting in RevPAR of approximately $269. This RevPAR result represents an approximate increase of 197% versus July 2020 and an approximate increase of 14% versus July 2019. "Our portfolio continues to deliver strong operational metrics as evidenced by the 14% increase in RevPAR for the month of July compared to the same month in 2019," said Richard J. Stockton, Braemar's President and Chief Executive Officer. "These results continue to be driven by strong leisure demand at our luxury resort properties as well as a ramp up of the performance of our urban hotels. Total revenues for Bardessono Resort and Spa, Hotel Yountville, and Pier House Resort for August and September are forecasted to be more than 30% higher than the same months during 2019. Looking ahead, we anticipate these trends continuing as our forward bookings remain strong."

16:15 EDT FPL announces agreement for clean energy infrastructure investment in Florida - Florida Power & Light Company, or FPL, announced a comprehensive, four-year rate settlement agreement developed jointly with the Florida Office of Public Counsel - the state's consumer advocate - as well as the Florida Retail Federation, the Florida Industrial Power Users Group and the Southern Alliance for Clean Energy, that would phase in new rates starting in 2022. The proposed agreement reflects a nearly 40% reduction in FPL's proposed January 2022 base rate revenue increase, from $1.1B to $692M, driven partly by a reduction in the company's originally proposed return on equity midpoint from 11.5% to 10.6%. Likewise, FPL's 2023 requested revenue increase would be reduced by nearly 10%, from $605M to $560M. The agreement would support continued long-term investments in infrastructure, clean energy and innovative technology - including the largest solar buildout in the United States - while keeping FPL's typical residential customer bills well below the national average through the end of 2025. The agreement would resolve FPL's current base rate proceeding and directly support FPL's groundbreaking "30-by-30" plan to install 30M solar panels in Florida by 2030, which remains ahead of schedule and under budget. In addition to solar energy, the settlement agreement would support FPL's green hydrogen pilot project in Okeechobee County, an innovative technology that could one day unlock 100% carbon-free electricity that's available 24 hours a day, as well as the FPL Manatee Energy Storage Center, the world's largest integrated solar-powered battery system that's projected to begin serving customers later this year. The agreement would also enable FPL to continue building a stronger, smarter and more storm-resilient energy grid in the face of Florida's frequently severe weather. FPL is a subsidiary of Juno Beach, Florida-based NextEra Energy.

16:13 EDT Coinbase sees Q3 trading volume lower than in Q2 - The company states: "In July, reta il MTUs and total Trading Volume were 6.3 million and $57.0 billion, respectively, as cr ypto asset prices and cr ypto asset volatility declined significantly relative to Q2 levels. August month-to-date, reta il MTUs and Trading Volume levels have slightly improved compared to July levels but rema in lower than e arlier in the ye ar. As a result, we believe reta il MTUs and total Trading Volume w ill be lower in Q3 as compared to Q2."

16:09 EDT Virtus Investment reports preliminary total AUM $180.3B as of July 31 - In addition, the company provided services to $3.8B of other fee-earning assets that are not included in assets under management.

16:06 EDT Qiagen, GT Molecular collaborate over COVID wastewater detection solution - Qiagen and GT Molecular have started to offer a complete wastewater workflow solution designed to enable surveillance of COVID-19 outbreaks by U.S. and Canadian laboratories, with future options to offer the solution in other countries. The workflow leverages QIAGEN's sample-preparation expertise and its innovative QIAcuity digital PCR system, which hosts GT Molecular's digital SARS-CoV-2 Wastewater Surveillance Assay. The assay was developed to comply with the CDC guidelines for the United States National Wastewater Surveillance System. The complete workflow has become available as of the beginning of August, when the assay launched. In response to the pandemic and the demand from authorities for health data about broad sections of the population, the solution sets new standards. It allows for the quantification of SARS-CoV-2 in wastewater in less than two and a half hours, compared to up to 6 hours with other dPCR systems. Furthermore, the integration of QIAGEN's AllPrep PowerViral DNA/RNA Kit, which leverages QIAGEN's patented Inhibitor Removal Technology, with a robust multiplex dPCR detection on the QIAcuity Digital PCR System, enables highly accurate viral RNA analysis from typically very variable wastewater samples.

16:01 EDT Boeing reports 28 commercial airplane deliveries in July - Earlier, Boeing reported 28 jets delivered in July and 31 gross jet orders in its commercial program. Reference Link

15:56 EDT SC Health Corporation (Class A Stock) trading halted, volatility trading pause

15:10 EDT E-Home Household to expand household services business via stake acquisitions - E-Home Household Service Holdings announced that its affiliated variable interest entity, Pingtan Comprehensive Experimental Area E Home Service Co., or "E-Home Pingtan," had entered into an equity transfer agreement to acquire 33% equity interests of "Happiness Yijia" in cash; an equity transfer agreement to acquire 100% equity interests of "Jin Ri Dao Jia" in cash; and an equity transfer agreement to acquire 55% equity interests of "Zhi Xie Education" and 55% equity interests of "Ju Shang Enterprise" in cash. Wenshan Xie, Chairman and CEO of the company, commented, "We believe that with the recent three-child policy, the demand for child care, housekeeping and other household services will further rise, and our acquisitions of stakes in the four companies will help further expand our household services and enable us to better seize the opportunities brought by the three-child policy."

14:37 EDT Micron still seeing 'robust' cloud demand, auto 'very strong' as well - Speaking at the Technology Leadership Forum, Micron CFO David Zinsner told KeyBanc analyst John Vinh that, "For the third quarter, we see very positive trends both for DRAM and NAND. In Cloud, we're still seeing robust demand. On the enterprise front, which had been negatively impacted by COVID, we've seen things improve as more people migrate back to offices. On the Mobil front, I would characterize as stable right now but expect to see it get stronger in the second half of the year. On the automobile side and industrial business... that is very strong. We're struggling to keep up with that demand. On the consumer front, seeing a slowdown which is not surprising during the summer months. PC is mixed." "Inventory at suppliers is very low. On distribution side, inventories are low as well. On the consumer side, inventories are in good shape," he added.

14:26 EDT Pershing Square acquires initial stake in Universal Music Group - Pershing Square Holdings (PSHZF) announced that Pershing Square Holdings Ltd., Pershing Square L.P., and Pershing Square International Ltd., through an affiliated entity, have acquired 128,555,017 Ordinary Shares of Universal Music Group, representing 7.1% of the company from Vivendi S.E. (VIVHY) for approximately $21.78 per share, or EUR18.58 per share at today's exchange rate. The total cash consideration of $2.8B represents an equity value for UMG of EUR 33B. PSH's share of the cash consideration is approximately $2.5B. PSH and its affiliates have the right to acquire up to an additional 2.9% of UMG's Ordinary Shares at the same price per share by September 9, 2021, which right Pershing Square intends to exercise.

13:58 EDT Sykes Enterprises provides regulatory update on Sitel merger - Sykes Enterprises announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 regarding the all-cash acquisition by Sitel Group expired at 11:59 PM ET on August 9, 2021. The proposed transaction has received antitrust clearance in other key foreign jurisdictions. The transaction, which is expected to be completed in the second half of 2021, remains subject to certain closing conditions, including the approval of SYKES' shareholders at its Special Meeting, which is scheduled for August 24, 2021 at 8 AM ET at the Rivergate Tower, 400 N. Ashley Drive, Suite 320, 3rd Floor, Conference Room A, Tampa, FL 33602. Upon the closing of the transaction, which was approved unanimously by the company's Board of Directors, SYKES will become a privately-held company and its shares will cease trading on Nasdaq.

13:13 EDT Moody's upgrades Advanced Micro Devices to Baa1, keeps under review for upgrade - Moody's Investors Service announced that it has upgraded the senior unsecured rating of Advanced Micro Devices and kept the rating under review for upgrade "following the company's exceptionally strong performance and outlook since Moody's initially placed the ratings under review in October 2020 following the company's announcement that it agreed to acquire Xilinx, Inc. in an all-stock transaction, which at the time was valued at approximately $35 billion." Both boards of directors and many regulatory authorities have approved the transaction, and subject to full regulatory approval, the acquisition is expected to close by the end of 2021, said Moody's, which added that the review for upgrade "reflects the credit positive nature of the proposed acquisition because, aside from all equity funding, it would diversify AMD's revenue and earnings sources, and broaden its portfolio outside of its core personal computer, server, and gaming end markets." Reference Link

12:58 EDT AeroCentury says filed notice with bankruptcy court on investment terms - In a regulatory filing earlier, AeroCentury disclosed that on August 9, 2021, in the United States Bankruptcy Court for the District of Delaware in the Chapter 11 case of AeroCentury Corp. and its two U.S. subsidiaries, JetFleet Management Corp., and JetFleet Holding Corp, the debtors filed notice with the bankruptcy court that an investment term sheet had been executed by AeroCentury with Yucheng Hu, Hao Yang, Jing Li, Yeh Ching and Yu Wang, and identifying such individuals as "plan sponsor" chosen by the debtors to provide equity investment of $11M into AeroCentury through the purchase of common stock from AeroCentury, as part of the debtors' plan of exit from Chapter 11. The filing noted: "As soon as practicable following the effective date, AeroCentury will make a cash dividend distribution to the Legacy ACY Shareholders in the aggregate amount of $1M, funded from the purchase price paid by plan sponsor for the New ACY Shares... Following the effective date, AeroCentury will have a board of directors initially consisting of five members, which will consist of three directors designated by Yucheng Hu, the 'lead investor,' and two directors to be mutually agreed upon by the lead investor and the current incumbent board of directors."

12:43 EDT Hub Group names Thomas LaFrance as general counsel and secretary - Hub Group (HUBG) announced that it has appointed Thomas P. LaFrance as EVP, General Counsel and Secretary of Hub Group."We are pleased to welcome Tom to the Hub Group team. His experience across multiple industries, including transportation, coupled with Mergers & Acquisitions, public company, corporate governance and regulatory experience is a great fit," said David Yeager, Hub Group Chairman and CEO. "Tom has the experience to guide Hub Group through this next phase of growth as an industry-leading supply chain solutions provider." LaFrance has held multiple General Counsel positions including most recently with National Grid (NGG).

12:00 EDT Yalla falls -15.1% - Yalla is down -15.1%, or -$2.04 to $11.51.

12:00 EDT Casper Sleep falls -18.2% - Casper Sleep is down -18.2%, or -$1.26 to $5.66.

12:00 EDT 3D Systems rises 38.3% - 3D Systems is up 38.3%, or $10.86 to $39.21.

12:00 EDT Lightning eMotors rises 51.8% - Lightning eMotors is up 51.8%, or $3.32 to $9.73.

11:43 EDT Dominion to convert 75% of passenger vehicles to electric power by 2030 - Dominion Energy announced a suite of carbon-reduction goals that will transform the fleet of more than 8,600 vehicles that serves millions of customers across 16 states. The Green Fleet initiative will help Dominion Energy achieve its goal of net zero carbon dioxide and methane emissions, while showing the way for clean-energy progress in the transportation sector, the largest contributor of greenhouse gas emissions in the U.S. Among Dominion Energy's commitments: 75% of passenger vehicles, including sedans and SUVs, will be converted to electric power by 2030. 50% of work vehicles - from full-size pickups and bucket trucks to forklifts and ATVs - will be converted by 2030 to plug-ins, battery electric vehicles, or vehicles fueled by cleaner-burning alternatives, such as hydrogen, renewable natural gas, and compressed natural gas. In the transition, the company will make use of trucks equipped with emissions-reducing ePTO systems. 100% of all new vehicles - from sedans to heavy-duty vehicles - purchased will be powered either by electricity or alternative fuels, after 2030. In support of the goals announced today, the company will expand infrastructure supporting EV charging and alternative fuels at local offices and other facilities.

11:04 EDT Allegiant Travel announces new aircraft, crew bases in Flint, Appleton - Allegiant Travel announced plans to establish two new aircraft and crew bases during the first quarter of 2022, at Flint Bishop International Airport in Michigan and Appleton International Airport in Wisconsin. "Flint and Appleton have been incredibly successful cities for Allegiant, where we've grown our operations steadily over the years," said Drew Wells, senior vice president of revenue and planning. "It makes perfect sense to establish aircraft and crew bases in these great communities, furthering our presence as a hometown airline. Having locally-based operations will mean opportunities for expanded hours, as well as more - and more frequent - flight offerings for local residents. These new bases will also be pivotal to stretching our network, increasing nonstop flight offerings throughout the country as demand for leisure travel continues to rebound." At Flint Bishop International Airport, Allegiant will begin base operations with three Airbus A320 aircraft and at least 89 crew members, maintenance technicians and support staff on February 16, 2022 - an investment of $75M. At Appleton International Airport, a $50M investment will include two locally-based Airbus A320 aircraft and bring at least 66 new jobs to the community. Allegiant will begin base operations at ATW on March 2, 2022.

10:32 EDT MyMD's Oravax Medical preparing to commence trials for COVID-19 vaccine - MyMD Pharmaceuticals (MYMD) reported that its subsidiary Oravax Medical, partially owned with its majority partner Oramed Pharmaceuticals (ORMP), is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally. Oravax's COVID-19 vaccine is being developed for use both as a standalone vaccine and as a booster for people who have been previously vaccinated for COVID-19. Oramed and MYMD are currently evaluating several options with respect to their interest in Oravax including a potential distribution of Oravax shares to both Oramed and MYMD shareholders. This would make Oravax a publicly held company that may then apply for listing on Nasdaq if eligible. MyMD's ownership of Oravax consists of 13% of Oravax's outstanding shares of capital stock and a 2.5% royalty on all future net sales. MyMD recently announced that a human cell research study of its lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine storm, a major cause of severity and death in COVID-19 patients. A Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation is expected to begin by the fourth quarter of 2021 with initial trial data expected in the first quarter of 2022.

10:21 EDT Sysco: July FY22 sales were more than $4.9B

10:09 EDT Ormat Technologies signs 10MW long-term resource adequacy agreement with PG&E - Ormat Technologies (ORA) announced that it has signed a Long-Term Resource Adequacy agreement with Pacific Gas and Electric Company (PCG) for its 20MW/40MWh Pomona-2 facility that is currently under construction. The Pomona 2 project will be located adjacent to and will utilize existing infrastructure from the operating Pomona 1 facility. Under the 10-year agreement, the Pomona-2 facility will provide 10MW of Resource Adequacy to PG&E and will also participate in the energy and ancillary services markets run by the California Independent System Operator. Ormat will undertake engineering, procurement and construction of this project, leveraging its core EPC capabilities and expects the project to begin commercial operation by October 2022. The Pomona-2 facility will add 20MW/40MWh to Ormat's current 83MW/176MWh operating energy storage portfolio and supports Ormat's plans to add between 200-300MW of additional energy storage projects by the end of 2023. The Long-Term Resource Adequacy agreement with PG&E was recently filed with the Public Utilities Commission for approval.

10:06 EDT Sysco: Food away from home 'vibrant,' 'healthy'

10:04 EDT Epam Systems announces acquisition of Colombia-based S4N - Epam Systems announced that it is expanding its global footprint within the Latin American region with the acquisition of Colombia-based S4N, which it calls "a leading software development services firm specializing in the design and development of modern software products and enterprise platforms." Victor Dvorkin, SVP, Head of Global Delivery at Epam, said: "The acquisition of S4N enables our continued progress in building a more agile, diverse and global delivery organization. With the addition of hundreds of talented engineers in key LATAM locations, we can deliver enhanced and truly multidisciplinary engagements to our customers in the Americas and around the world."

10:02 EDT Fulcrum Therapeutics trading halted, volatility trading pause

10:00 EDT Yalla falls -13.7% - Yalla is down -13.7%, or -$1.85 to $11.70.

10:00 EDT 3D Systems rises 25.4% - 3D Systems is up 25.4%, or $7.19 to $35.54.

10:00 EDT Lightning eMotors rises 55.1% - Lightning eMotors is up 55.1%, or $3.53 to $9.94.

09:58 EDT Nano-X Imaging to acquire Zebra Medical Vision in deal worth up to $200M - Zebra Medical Vision announces it has entered into an agreement to be acquired by Nanox by a merger transaction in a deal valued at up to $200M. $100M will be paid upfront and up to additional $100M, subject to certain deductions, will be paid upon achievement of certain milestones. As a result of the acquisition, the medical imaging pioneers will leverage Zebra-Med's industry-leading team, cutting-edge AI technology and cloud capabilities, and unprecedented regulatory framework to form the next-generation medtech juggernaut.

09:56 EDT Sysco: Restaurant foot traffic up since March 2021, surpassing grocery

09:55 EDT Sysco: Reinstatement of buyback program to commence in FY22

09:47 EDT Squarespace falls -12.4% - Squarespace is down -12.4%, or -$6.12 to $43.38.

09:47 EDT Oak Street Health falls -14.9% - Oak Street Health is down -14.9%, or -$9.38 to $53.56.

09:47 EDT 3D Systems rises 22.2% - 3D Systems is up 22.2%, or $6.30 to $34.65.

09:43 EDT 808 Renewable Energy enters into cooperation agreement with EZGO Technologies - 808 Renewable Energy announces the Company has established a strategic cooperation relationship with EZGO Technology to team up together on OEM co-manufacturing. A tri-party agreement has been executed to have EZGO to handle the chassis and frame production, and to have Coleitec Composites Technology Co., Ltd. to handle the composite material production.

09:40 EDT Canadian National says 'continues to have a better bid' for Kansas City Southern - CN (CNI) issued a statement regarding CN's proposed "pro-competitive" combination with Kansas City Southern (KSU) and Canadian Pacific Railway's (CP) announcement that it has made another "inferior proposal" to acquire KCS, stating in part: "CN and KCS' agreed transaction remains superior and the best option for both companies' stakeholders to deliver on a combination that will enhance competition and provide new servicing options for customers... CN's proposal delivers an implied premium of 45% to KCS shareholders as well as participation in the significant upside of the combined company. CN's accepted proposal also reflects an 8% premium over CP's latest inferior offer of $300 per share. CN and KCS' joint voting trust application, which was filed on May 26, 2021, is currently under review by the Surface Transportation Board, or 'STB.' We await the STB's decision following a comprehensive comment period which resulted in overwhelming support from customers, suppliers, elected officials, organized labor, local communities and other stakeholders. CN and KCS are confident that the voting trust meets all the standards set forth by the STB and believe that, after a fair and thorough review by the STB, it should be approved. KCS shareholders will receive the merger consideration immediately upon the closing of CN's voting trust. Together, CN and KCS would create the premier railway for the 21st century, connecting ports in the United States, Mexico and Canada to expand North American trade and power economic prosperity. We will continue to take the necessary steps to deliver the many compelling benefits of this transaction to CN and KCS stakeholders."

09:35 EDT Adial Pharmaceuticals awarded U.S., International patents for AD04 - Adial Pharmaceuticals provided an update on recently issued patents for the use of Adial's lead asset, AD04, for the treatment of both Alcohol Use Disorder and Opioid Use Disorder. AD04 is currently being evaluated in the Company's ONWARD trial, a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD, which is being conducted in seven countries. Recently issued patents: U.S. Patent Number 16,807,379 covering the use of AD04 as a treatment for OUD in patients with a specific genetic biomarker in the serotonin transporter gene. Canadian Patent Number 2716498 covering the use of AD04 for both OUD and AUD in patients with specific genetic biomarkers in the serotonin transporter gene. Israeli Patent Number 262874 covering the use of AD04 as a treatment for OUD in patients with specific genetic biomarkers in the serotonin transporter gene. Brazilian Patent Number PI09084258 covering the use of AD04 as a treatment for OUD in patients with specific genetic biomarkers in the serotonin transporter gene. The Company believes AD04 may hold significant potential for the treatment of OUD since the physiology and neurotransmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist.

09:32 EDT PAVmed's Lucid Diagnostics launches first Lucid Test Centers - PAVmed announced that its majority owned subsidiary Lucid Diagnostics has begun testing patients referred by primary care physicians at three Lucid Test Centers in the Phoenix metropolitan area. Patients with chronic heartburn, also known as gastroesophageal reflux diseases, who are referred to the centers undergo a rapid non-invasive office procedure, performed by Lucid-employed clinical personnel, using Lucid's EsoCheck Cell Collection Device to collect surface esophageal cells for its EsoGuard Esophageal Test. The three Lucid Test Centers operate in leased medical office suites located in Scottsdale, Tempe and Glendale, Arizona and are staffed by an EsoCheck-trained nurse practitioner and medical assistant employed by Lucid. Lucid estimates that a single nurse practitioner will be able to perform up to twenty EsoCheck procedures per day and expects each center to cover its personnel and medical office leases costs with only a few tests per week. Lucid has hired its first sales representative specifically tasked with calling on PCPs and whose efforts, working with regional business and market development managers, are now driving EsoGuard referrals to the Phoenix area test centers.

09:27 EDT AeroCentury trading halted, news pending

09:25 EDT DigitalBridge to acquire controlling stake in Vertical Bridge, no terms - DigitalBridge announced that funds affiliated with DigitalBridge Investment Management, the Company's investment management platform, have reached a definitive agreement to acquire a controlling stake in Vertical Bridge Holdings, a private owner and operator of wireless communications infrastructure in the United States. "Vertical Bridge is the leading independent tower platform in the U.S., led by the preeminent tower management team in the industry," said Steven Sonnenstein, Senior Managing Director of DigitalBridge Investment Management. "Significant acceleration in 5G infrastructure spending in the U.S has created a tremendous long-term growth opportunity for telecommunications infrastructure and demonstrated that investments to support the next generation of mobility continue to be a powerful thematic. By consolidating Vertical Bridge's ownership via our fund management business, we will not only extend our long-standing relationship, but we will be even better positioned to support the Vertical Bridge team as they build on their market leadership and capitalize on exciting growth opportunities." The transaction is subject to various regulatory approvals and is expected to close during the fourth quarter of 2021. Financial terms of the transaction were not disclosed.

09:20 EDT Athersys partner completes enrollment in TREASURE study - Athersys announced that its partner, Healios K.K., has completed enrollment in its TREASURE study in Japan, evaluating MultiStem cell therapy treatment in patients who have suffered an ischemic stroke.

09:12 EDT Ascot Resources announces outlook for 2021 - Management is planning a number of activities for the remainder of 2021, which include: Continuing to progress on 2021 exploration plan at higher elevations to focus on prospective area near the Day Zone and north of Premier deposit. A second surface drill rig is planned to be added in the coming weeks. Progressing to the third stage of review comments from the regulators and NLG on Joint MA/EMA Application with a target to completion in Q3, 2021. Continuing to advance detailed engineering, Early Works construction program including the installation of the Ball and SAG mill in Q3 2021 and ordering of other long lead time equipment. Progressing the early works on the water treatment plant and water distribution system and haul road upgrades and installation of the construction camp.

09:10 EDT HP Inc. introduces HP Chromebook x2 11, HP Chromebase All-in-One Desktop - HP Inc. expanded its robust Chrome OS ecosystem for customers seeking ultimate versatility and mobility in today's hybrid world, with the introduction of the HP Chromebook x2 11 and the HP Chromebase 21.5 inch All-in-One Desktop. HP also announced the new Works With Chromebook certified HP M24fd USB-C Monitor for a seamless user experience when pairing with Chromebooks and other accessories.

09:09 EDT American International Holdings' LifeGuru adds new service features - American International Holdings announced that its LifeGuru online life-coaching platform subsidiary has added numerous, robust new service features along with important upgrades and enhancements to www.LifeGuru.me - triggering its ramp-up of coach recruitment initiatives. The LifeGuru online platform enables consumers to connect directly with a variety of expert life, executive, health and wellness, leadership, and career coaches worldwide for affordable, expert tele-video coaching and mentorship services from their laptop or mobile device. A partial list of additional features, enhancements and upgrades made to the LifeGuru.me site over the past several months includes: Upgraded Coach Services Hub: Provides coaches a simple-to-navigate "all under one roof" environment including: direct client inquiries, promotion of services, calendar management with session booking and scheduling, new payout and reporting features implemented and integrated with merchant payment system, and proprietary private, and secure in-house video conferencing; New Blog Section: Enables coaches to showcase their expertise, and promote their practice with distinctive content for current and prospective clients ; More Flexible Service Options: Offers three different coach subscription levels, including a "90-day free trial" option; Featured Coaches Carousel: Allows certain coaches to be featured on the Lifeguru.me home page; Auto Prompted Testimonials: At the conclusion of each session, prompts clients to leave genuine reviews which are displayed on each coach's profile; Website Mobile Optimization: Overall site enhancements for easier and seamless tele-video and interaction with coaches across all mobile devices and platforms.

09:06 EDT Comtech says during Q4 it was awarded a $1M contract for high power amplifiers - Comtech Telecommunications announced , that during its fourth quarter of fiscal 2021, it was awarded a $1.0M for high-power amplifiers from a major domestic prime contractor. These amplifiers, which utilize the latest in solid-state GaN transistor technology, are key transmit elements in a data communication system. They add to an installed base of Comtech solid-state high-power RF amplifiers previously delivered to this major domestic prime contractor.

09:03 EDT Robinhood to acquire Say Technologies for about $140M - Aparna Chennapragrada, Chief Product Officer, Robinhood, announced in a blog post: "One of our core values is Participation is Power. We think there's room for everyone in the financial markets and we're always working to help first-time investors become long-term investors. We're excited to share that Robinhood Markets has signed an agreement to acquire Say Technologies for approximately $140 million, subject to customary purchase price adjustments, in an all cash deal. Say is a mission-driven company that's built an innovative communication platform that makes it easier for investors to exercise their ownership rights. Like Robinhood, Say was built on the belief that everyone should have the same access to the financial markets as Wall Street insiders. We share a common goal of eliminating the barriers that keep people from participating in our financial system... As part of the Robinhood family, Say will keep offering its proxy voting services and Q&A platform to existing customers. And together, we'll find new ways to expand what it means to be an investor through new products and experiences that democratize shareholder access." Reference Link

08:55 EDT Corning introduces cellular solutions to enable 5G connection indoors - Corning Incorporated introduced new high-performance cellular solutions designed to help network operators bring reliable 5G connection indoors with small-cell radio nodes that are easy to install and cost-effective to operate. 5G capabilities are at the forefront of enabling the world's most advanced connectivity and unrivalled network speeds. Today, 80% of mobile traffic originates or terminates indoors, and some 5G frequencies do not penetrate physical barriers, such as walls, as well as 4G/LTE frequencies. With the demand on bandwidth intensifying, network operators will require reliable systems that bring 5G indoors. Corning's Everon mmWave indoor small-cell systems are designed to deliver 5G-ready coverage in high-density environments - including office buildings, factories, hotels, hospitals, and classrooms - where large amounts of data must be managed and transmitted. These systems are designed to operate at commonly used frequencies, including 28 GHz and 39 GHz, for carrier networks and enterprise network operators who are looking to bring reliable 5G connectivity indoors.

08:54 EDT Roper Technologies to divest Zetec business in $350M transaction - Roper Technologies announced that it has reached a definitive agreement to sell its Zetec business to Eddyfi/NDT in an all-cash transaction valued at approximately $350M. Zetec has generated approximately $64M of revenue and $17M of EBITDA over the last 12 months. The Company expects this transaction to close at the end of this year, subject to customary closing conditions, including regulatory approvals.

08:53 EDT Mindset announces preclinical results from multiple psychedlic drug families - Mindset Pharma announced that compounds from its Family 2, comprised of novel psilocybin/psilocin analogs, and Family 4, comprised of novel DMT/5-MeO-DMT analogs, have demonstrated superior efficacy, safety and shorter duration of action in head-to-head preclinical comparisons with their reference drugs. Mindset's Family 2 compounds are next-generation psilocybin and psilocin analogs optimized for in-clinic settings and Mindset's Family 4 compounds are DMT and 5-MeO-DMT inspired drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

08:52 EDT Kornit Digital says more confident than ever in outlook - Says pipeline has never been stronger. Says experiencing strong tailwinds. Says Voxel8 acquisition will help to accelerate 4.0 strategy. Says had very strong first half. Says more confident than ever in outlook for rest of the year and next year. Says will continue to invest in growing the organization. Comments taken from Q2 earnings conference call.

08:51 EDT GCM Grosvenor board approves dividend of 9c per share - GCM Grosvenor's Board of Directors approved a $0.09 per share dividend for the second quarter of 2021 payable on September 15, 2021 to shareholders on record September 1, 2021

08:46 EDT IDT Corp partners with Jonathan Mensah - IDT announced a partnership with professional soccer player Jonathan Mensah. Jonathan is a defender and team captain for Major League Soccer's Columbus Crew. Through the partnership, Jonathan will support IDT's BOSS Revolution brand -- including its international money transfer, voice calling and mobile top-up services -- as spokesperson and ambassador in its advertising campaigns. He will be featured across broadcast, print, and digital media, and will endorse BOSS Revolution across his digital fanbase.

08:44 EDT Cerus announces CMS P-codes issuance for billing of INTERCEPT products - Cerus Corporation announced that the U.S. Centers for Medicare & Medicaid Services, CMS, has granted permanent Healthcare Common Procedure Coding System HCPCS Level II codes for Pathogen Reduced Cryoprecipitated Fibrinogen Complex, or INTERCEPT Fibrinogen Complex , and Pathogen Reduced Plasma, Cryoprecipitate Reduced. These new P-codes, P9026 and P9025, respectively, are effective October 1. "By providing a means for hospitals to bill for Cerus' recently-approved products in the hospital outpatient setting, CMS' decision to establish these new codes enables provider and patient access to continued innovation in transfusion medicine," said Jessica Hanover, Ph.D., Cerus' vice president, corporate affairs. "We are pleased that these codes will facilitate hospital utilization of our new pathogen reduced blood products, which address critical unmet needs for so many patients." The establishment of HCPCS Level II P-codes follows the announcement earlier this month that CMS has granted a new technology add-on payment for IFC within the Medicare Hospital Inpatient Prospective Payment System . In November 2020, the U.S. Food and Drug Administration granted approval of the INTERCEPT Blood System for Cryoprecipitation, which is used to produce IFC as well as Pathogen Reduced Plasma, Cryoprecipitate Reduced. IFC was previously granted FDA Breakthrough Device designation based on its potential to improve treatment of massive hemorrhage, a life-threatening medical condition.

08:43 EDT AYRO receives additional $2.9M purchase order for Club Car Current EV - AYRO announced the receipt of an additional purchase order valued at $2.9M for the 2022 Club Car Current. This comes nearly two months after the announcement of the initial $2M purchase order for the Club Car Current and brings total orders to $4.9M to date since the product's introduction in June 2021, demonstrating strong demand for this compact and customizable delivery EV. The Club Car Current is being assembled by Karma Automotive at the Karma Innovation and Customization Center in Moreno Valley, California. KICC's supply chain capabilities and resources allow AYRO to respond to customer and market demands despite industry-wide supply chain shortages. Gallery is customizing the Club Car Current to support the growing demand for on-board food and retail delivery options. Element Fleet Management is also offering the Club Car Current alongside its financing, maintenance, roadside assistance, and other fleet services and solutions.

08:41 EDT Tattooed Chef launches new items at Sprouts Farmers Market - Tattooed Chef (TTCF) announced it has launched four entree bowls including two new flavors at Sprouts Farmers Market in approximately 340 stores. The four entree bowl flavors are now available to Sprouts Farmers Market shoppers, including the new Buffalo Cauliflower Mac & Cheese Bowl and Spicy Thai Bowl. "I am excited to introduce our newest meat alternative, our gluten free plant based chicken in our Spicy Thai Bowl," said Sarah Galletti, Founder and the Tattooed Chef. "We believe it's important to have a variety of meat alternatives in our value-added products to appeal to the growing set of consumers who are newer to plant based eating." These bowls are available in the frozen section at Sprouts Farmers Market (SFM) stores nationwide. They require a one-step preparation and are ready to eat within 6-7 minutes.

08:39 EDT Iteris, Wejo team on applications of connected vehicle data for efficient roads - Smart mobility infrastructure management company,Iteris (ITI) and Wejo, a firm in connected vehicle data, announced that they have entered into an agreement to deliver enhanced connected vehicle data content to Iteris' public-sector and commercial customers throughout North America. Under the terms of the agreement, Iteris will join Wejo's partner program to provide new and existing customers with real-time movement data from more than 11 million connected vehicles in North America. In addition, Wejo will join Iteris' ecosystem of mobility intelligence providers, empowering public-sector and commercial enterprise customers in the transportation space nationwide with Wejo's connected vehicle data. Connected vehicle data characteristics will combine with additional layers of real-time traffic and weather information, incremental predictive inputs and artificial-intelligence capabilities from Iteris' ClearMobility Cloud. The combination will enable a new level of insights in areas such as commuter information, traffic mitigation, road network management and studying road utilization. "We are excited to announce this partnership, which will make Wejo's near real-time connected car data available to Iteris' public-sector and commercial enterprise customers nationwide for the first time," said Richard Barlow, CEO at Wejo. "Our value-added insights will enhance and improve Iteris' product offerings, and ultimately contribute to improved safety and reduced congestion on roadways throughout North America, while helping to shorten journey times and providing car owners with a materially better driving experience." This news comes on the heels of growing interest in connected vehicle data and promise for its applications across sectors. Microsoft (MSFT), Palantir Technologies (PLTR) , Sompo Holdings and General Motors (GM) have all become strategic investors in Wejo as part of the definitive agreement it made to enter a business combination with Virtuoso Acquisition (VOSO) in a transaction expected to close later this year.

08:38 EDT Vallon Pharmaceuticals expects cash to fund operations into 3Q22 - As of June 30, 2021, the Company had cash and cash equivalents totaling approximately $10.5 million, which the Company expects will provide funding for its ongoing business activities into the third quarter of 2022.

08:36 EDT Pacira reports preliminary sales of $42.1M for July - Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera degrees of $40.9 million and $1.0 million, respectively, for the month of July 2021. EXPAREL average daily sales for the month of July 2021 were 117 percent of July 2020. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. EXPAREL selling days were 21 in July 2021 and 23 in July 2020. "The continued growth of EXPAREL reflects its accelerating deployment as the opioid-free local analgesic of choice given its enduring efficacy, excellent safety profile and proven ability to reliably facilitate surgical migration to outpatient sites of care," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Following record-level revenue in the second quarter, EXPAREL demand remains strong leaving us confident in our ability to achieve our five-year goals of top line growth in at least the high teens and operating margins that exceed 50 percent." The company's net product sales were negatively impacted by the COVID-19 pandemic in 2020 due to the significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020, allowing EXPAREL sales to return to year-over-year growth in June 2020. However, while many restrictions have since eased and COVID-19 vaccines become more widely available and administered to the general public, it is still unclear how long it will take the elective surgery market to normalize, or if restrictions on elective procedures will recur due to COVID-19 variant strains or otherwise.

08:34 EDT Plug Power breaks ground on green hydrogen production plant in Georgia - Plug Power broke ground on the site of a green hydrogen production plant in Camden County, Georgia, where 15 tons of liquid green hydrogen will be produced per day. By investing $84M into the facility, Plug Power affirms its continued commitment to establishing the first North American green hydrogen supply network. The plant, which will serve customers in the southeastern U.S., will produce liquid green hydrogen using 100% renewable energy with the help of at least 24 full-time, local employees. Andy Marsh, CEO of Plug Power, said the location of the plant is a part of the company's larger strategic plan to offer green hydrogen that is cost-competitive with fossil fuel energy to its customers looking to meet their sustainability goals. The groundbreaking of the plant also serves as a milestone for local and state officials who have worked to attract more innovative jobs to the region.

08:31 EDT Intel, SADA launch cloud optimization program - SADA announces a pilot program with Intel (INTC) that is intended to ensure its customers' Google Cloud Platform (GOOG;GOOGL) environments are performing as well and as cost-effectively as possible. The new program officially launched earlier this month and currently includes more than a dozen companies. Initially the program will include some of SADA's largest customers, but over time it might be made available to all customers. Throughout the program, SADA will work with their customers and Intel on their workload placement, cost and performance benchmarking, and GCP configuration to determine how its technology can help customers reduce their total cost of ownership and improve their return on investment. By using Intel hardware that has been optimized for a specific environment, companies often save money and achieve better performance.

08:29 EDT Huntington Ingalls awarded $273M US Navy aircraft carrier, maintenance contract - Huntington Ingalls Industries' Technical Solutions division announced that it has been awarded a five-year contract with a total value of $273M to support the U.S. Navy's carrier engineering maintenance assist team, surface engineering maintenance assist team for west coast surface ships, and other maintenance and material readiness programs. Work performed on the contract will support maintenance and planning for the overhaul and repair of equipment and systems including hull, mechanical and electrical; aviation equipment and systems; command, control, communications, computer and intelligence; and combat support systems. Work will be performed within the U.S. and internationally during operational deployments.

08:28 EDT Global Crossing Airlines enters revenue service - Global Crossing Airlines Group is pleased to announce that as of August 7, 2021, it has begun passenger revenue operations as the newest US airline. Flying the Airbus A320 family, the airline provides charter flights to U.S, Canadian, Caribbean, and Latin American destinations from its hubs in Miami and Atlantic City. GlobalX flies for casinos, cruise lines, major hotel and resort destinations, and incentive groups.

08:26 EDT Revive Therapeutics provides update on psychedelics clinical product pipeline - Revive Therapeutics is pleased to provide an update on the Company's psychedelics development and clinical programs with a focus on psilocybin. The Company is working with the Board of Regents of the University of Wisconsin System under a clinical trial agreement to conduct a Phase I/II clinical study to evaluate the safety and feasibility of psilocybin in adults with methamphetamine use disorder. Study start-up activities have taken place and enrollment activities are to continue throughout the remainder of the year. As a result of the study, clinical data will provide proprietary and valuable information on the safety, efficacy and dosing of psilocybin to support future pivotal FDA clinical studies in oral forms of delivery including oral thin film strips. The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin. In addition, the Company will have exclusive access to key intellectual property from this study to support development, regulatory and commercial initiatives. The Company is advancing the research and intellectual property acquired from PharmaTher Holdings on psilocybin as a potential solution to managing TBI and stroke. Preclinical studies demonstrated that psilocybin, given after injury, improved cognitive function in TBI mice. The Company is proceeding to an FDA clinical study to be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy. Start-up activities have already begun and patient enrollment is expected to commence in Q4-2021. The Company has initiated the product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films, to develop and manufacture a proprietary psilocybin oral thin film strip for mental illness, substance abuse and neurological disorders. Research grade prototypes will be available to evaluate dosing and delivery rates in various dosage forms with the expectation to conduct clinical studies in 2022. Under its research collaboration with North Carolina State University, the Company is developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams, Professor and Researcher at NC State. The biosynthetic platform developed by Dr. Gavin Williams provides a potentially simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli. Certain technical milestones have been achieved to date, offering a clear path towards completing validation methods to demonstrate a novel yet simple production process of biosynthetic psilocybin that can be used at a critical scale for clinical and commercial use. The Company recently entered into an agreement with the University of Health Sciences Antigua to utilize Revive's novel psychedelic-assisted therapies including its tannin-chitosan delivery system and to pioneer the clinical research and development of psychedelics in Antigua and Barbuda. Clinical research will be conducted at the University in Q4-2021 with the aim for commercialization in 2022 in Antigua and Barbuda. Once approved for sale, the Company will seek commercial partnerships with specialty pharmaceutical companies in the Caribbean and Latin America.

08:21 EDT NuCana appoints Jeffrey Bloss as Chief Medical Officer - NuCana announced the appointment of Jeffrey Bloss, M.D. as Chief Medical Officer. Bloss will be based in NuCana's US offices located outside Boston, MA. Jeffrey Bloss, M.D. brings over 25 years of leadership experience in oncology at multiple biopharmaceutical companies including Astellas, GlaxoSmithKline, Xencor, Onyx, Genentech and Eli Lilly.

08:19 EDT Sabina Gold & Silver reports mineralization at Hook Target - Sabina Gold & Silver Corp is pleased to announce initial results from the company's spring drilling program completed at the Hook Target, which has been identified as a key link along a mineralized trend hosting the Goose Main and Nuvuyak gold deposits, on its 100%-owned Back River Gold Project in Nunavut, Canada. For the first half of this year, exploration was focused on the southern mineralized trend that hosts Goose Main and Nuvuyak. The Hook target, which was thought to be the link between these deposits received the bulk of the meterage of this spring's program. Drill testing within the trend is highlighted by hole 21GSE600 which returned 5.42 g/t Au over 28.05 m, including 12.68 g/t Au over 5.30 m, returning the highest gram-meter intercept within the target trend to date. The intercept through the fold nose of the antiform sits within a 50.50 m length of anomalous gold mineralization. representing a key link in unlocking the trend by identifying a robust area for potential resource growth through further exploration. Three additional drill holes were also completed within the trend during the 2021 spring program which continued to further advance the geological controls and refine targets highlighted by broad mineralizing intercepts including 10.05 g/t over 8.50 m in drill hole 21GSE598B, 1.72 g/t over 10.30 m in drill hole 21GSE599 and 1.67 g/t over 15.55m in drill hole 21GSE590. Drill advancement at the Hook target area has become an important focus for exploration to establish future resource growth and mining synergies. An approximate 1,500 m of F1 antiform stratigraphy is identified to be relatively continuous from the daylighting of the Goose Main deposit to the furthest down plunge mineralization intercepts at Nuvuyak. A total of 450 m of exploration plunge length is interpreted to be open between these two deposits establishing a very prospective area for exploration and additional resource opportunity. The Goose Main deposit currently hosts an open pit and underground Proven reserve of 548,000 oz at an average grade of 4.60g/t and an additional open pit and underground Probable reserve of 301,000 oz at an average of 4.96 g/t. The Nuvuyak deposit currently hosts an initial NI 43-101 compliant Inferred resource of 583,000 oz at an average grade of 7.50 g/t and remains open in all directions. Drill holes in this release targeted an area surrounding key features at the Hook Target that are demarked by a quartz feldspar porphyry dyke hosted in an interpreted early structural setting within the Lower Iron Formation. The southern envelope of the demarking structure is interpreted as an important intersection lineation where in contact with the LIF stratigraphy, as it appears to be spatially associated with a key gold structure. Drill hole 21GSE600 is located approximately 120 m down plunge along the unfolded D2 trend of the Goose Main deposit and 330 m up plunge from the Nuvuyak deposit. Mineralization within the drill hole is noted as fine - to medium- grained pyrrhotite occurring as replacement bands of the stratigraphy and fracture infills. Lesser arsenopyrite occurs locally associated with fine chlorite and silica veins/alteration. Visible gold was frequent within the main interval occurring as fine specks throughout the drill core intercept. The spring drilling program at the Goose property is now complete with all drill holes totaling 4480 m which included the focused testing of five drill holes at the Hook Target, twelve drill holes testing earlier staged target areas, and an additional six drill holes supporting geotechnical investigations.

08:16 EDT Palo Alto Networks appoints Amit Singh to Chief Business Officer - Palo Alto Networks announced the expansion of its management team, with Amit Singh moving into the new role of Chief Business Officer and BJ Jenkins joining the company in the role of president. The appointments are effective immediately. Palo Alto Networks has reported notable momentum over the last financial year, with the business benefiting from customers adopting products across its Strata, Prisma and Cortex security platforms. As chief business officer, Singh will focus on bolstering the strategic customer relationships in partnership with Jenkins on the company's large deals. Additionally, he will partner with Chief Product Officer, Lee Klarich, on driving the cross-functional speedboats that have helped deliver Palo Alto Networks' industry-leading products. Singh's successful three-year tenure as Palo Alto Networks' president uniquely positions him for this role.

08:12 EDT Finch Therapeutics expects cash to fund expenditures into mid-2023 - Finch's cash and cash equivalents as of June 30, 2021 was $168.1 million compared to $99.7 million as of December 31, 2020. Finch expects that the cash and cash equivalents it had on hand at June 30, 2021 will be sufficient to fund operating expenses and capital expenditures into mid-2023.

08:11 EDT Harmony Biosciences provides update on upcoming milestones - Enrollment continues in Harmony's Phase 2 clinical trial evaluating the safety and efficacy of pitolisant for the treatment of EDS and other symptoms in patients with PWS and is on track to achieve top line data in the first half of 2022. In June 2021, Harmony initiated a Phase 2 clinical trial to evaluate the safety and efficacy of pitolisant for EDS and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy. Top-line results are anticipated in the second half of 2022.

08:10 EDT Ashford regains compliance with NYSE listing standards - Ashford announced that on August 9 the Company received written notice from the NYSE American stating that the Company has regained compliance with all of the continued listing standards set forth in Part 10, Section 1003 of the NYSE American Company Guide. By meeting the continued listing requirements, Ashford has resolved its continued listing deficiency and, effective at the start of trading on August 10 the ".BC" designation, signifying noncompliance with the Exchange's listing standards, will be removed from the "AINC" trading symbol.

08:09 EDT Commvault partners with ORock Technologies to expand data protection - ORock Technologies announced it has entered into a partnership with Commvault to expand data protection and offer a seamless migration to the cloud for mission-critical workloads. This cost-effective solution is ideally suited for any business operating in a highly regulated industry as well as any federal, state, local or education government agency seeking comprehensive backup and recovery in a secure cloud environment.

08:08 EDT PhaseBio announces approval of bentracimab IND - PhaseBio announced that the investigational new drug, or IND, application for bentracimab submitted to the Center for Drug Evaluation, or CDE, of the China National Medical Products Administration, or NMPA, in collaboration with development partner, SFJ Pharmaceuticals has been approved. Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta/Brilique. With approval of the IND, PhaseBio and SFJ are authorized to begin enrolling patients in China into REVERSE-IT, the ongoing global Phase 3, multi-center, open-label, prospective single-arm trial designed to study reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or an invasive procedure. PhaseBio and SFJ anticipate enrolling the first patients at sites in China later in 2021, after the REVERSE-IT trial has reached its interim enrollment milestone expected in mid-2021. Patients enrolled in China are expected to contribute to the completion of full enrollment of the trial, post interim analysis.

08:06 EDT Protagonist Therapeutics resolves contract dispute with Zealand Pharma - Protagonist Therapeutics(PTGX) announced it has resolved its Collaboration Agreement dispute with Zealand Pharma (ZEAL) by reducing future development and sales milestone payments and royalties owed to Zealand for Protagonist's product candidate rusfertide under the companies' 2012 Collaboration Agreement. Under the terms of an agreement that ends arbitration proceedings Protagonist initiated in 2020, future development and sales milestone payments (other than $2.5M in near-term milestones) and royalties for rusfertide have been reduced by 50%. Milestones and royalty payments will be due for sales and milestones achieved by either Protagonist or any future rusfertide licensee or partner. Protagonist will also make a $1.5M payment to Zealand in August 2022.

08:05 EDT Cumulus Media's Westwood One and the NCAA renew partnersip - CUMULUS MEDIA's Westwood One and the National Collegiate Athletic Association, or NCAA, have entered into a multi-year renewal, maintaining Westwood One's place as the official network audio broadcast partner of the NCAA for many years to come. Westwood One has broadcast the NCAA Men's Basketball Tournament since 1982 and every game of NCAA March Madness on multiple platforms since 2005. Under the terms of the deal, Westwood One retains exclusive broadcast radio, digital audio, distribution, and licensing rights for all 90 NCAA Championships, including the NCAA Men's and Women's Basketball Tournaments and the Final Fours.

08:04 EDT Home Depot creates 500 new jobs in Baltimore - The Home Depot has opened three new distribution centers in Sparrows Point's revitalized Tradepoint Atlantic development. The 1.5M square-foot campus will bring nearly 500 new full- and part-time jobs to Baltimore and provide even faster delivery options to customers in the region.

08:03 EDT Nikola expands sales, service dealer network in Northeastern United States - Nikola (NKLA) announced an expansion to its dealer network for its Class 8 truck sales and service coverage with the addition of Alta Equipment Group (ALTG). Alta Equipment Group plans to represent sales and service locations in New York, New Jersey, eastern Pennsylvania and other select areas in the New England region that have a growing opportunity in zero-emission technology for Class 8 trucks.

08:02 EDT Black Diamond Therapeutics announces appointment of Velleca to board - Black Diamond Therapeutics (BDTX) announced the appointment of Mark Velleca, M.D., Ph.D. to its board of directors. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. Velleca was most recently Chief Executive Officer of G1 Therapeutics (GTHX), where he grew the company from Series A through IPO and led the development of its first therapy from preclinical to FDA approval.

08:01 EDT InflaRx reports data from interim analysis of Phase IIa study of vilobelimab - InflaRx announces positive data from the first 10 evaluable patients in the ongoing Phase IIa open label study with vilobelimab in Pyoderma Gangraenosum. As previously announced, enrollment in the proof-of-concept study was completed with 19 patients, with 12 in the first two dose cohorts. Two out of the 12 withdrew from the study before reaching day 99 of the treatment, so only 10 patients were evaluable for the efficacy assessment on day 99. The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG. Out of the 10 patients evaluable for efficacy at day 99, four patients met the response criteria, with three of them achieving complete closure of the target ulcer. The three patients who showed clinical response with a PGA score of equal to or more than 3 with complete target ulcer closure had elevated C5a levels at baseline. InflaRx previously reported the clinical response for two of these three patients in February 2020. The third patient demonstrating complete target ulcer closure had been increased from the 1600mg dose group to the highest dose of 2400mg dose on day 57 of the study and closed the ulcer after the dose escalation. The other six patients all showed slight improvement in their condition according to the PGA definition. Overall, vilobelimab was well-tolerated and no new safety findings emerged. One patient experienced a delayed hypersensitivity in form of a skin rash which resolved upon discontinuation of vilobelimab

07:55 EDT Abeona Therapeutics appoints Edward Carr as Chief Financial Officer - Abeona Therapeutics announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Carr had served as Abeona's Chief Accounting Officer since January 2019. Carr joined the company in November 2018 as Corporate Controller, bringing more than 25 years of financial leadership experience serving in various finance roles of increasing responsibility.

07:52 EDT DraftKings Marketplace now live with NFT drops from athletes - DraftKings Marketplace, the NFT ecosystem designed by DraftKings, is now live and will feature its first Preseason Access Collection that drops later this week. The exclusive debut content will be provided by Autograph, and includes Preseason Access Passes from athletes such as Tom Brady, Wayne Gretzky, Tony Hawk, Naomi Osaka, Derek Jeter, Tiger Woods and more who will soon be announced. These sports-related NFTs will be available exclusively on Autograph.io and on DraftKings Marketplace. Customers nationally can join the first drops starting on August 11th, which will feature Tom Brady. "Autograph's Advisory Board includes some of the most iconic athletes ever, and we could not imagine a more fitting figure than Tom Brady to headline our first ever NFT drop on DraftKings Marketplace," said Matt Kalish, co-founder and president of DraftKings. "The overall NFT market has already surged to over $2.5 billion in sales volume for the first half of 2021, and so whether someone is well-versed or barely familiar with digital collectibles, we envision DraftKings Marketplace being a premier platform for all within a trend that is decidedly here to stay." With this launch, fans and collectors across the country with a DraftKings account can now access DraftKings Marketplace on desktop or mobile either directly through the website or via DraftKings' apps. Each featured athlete will begin by dropping a limited number of NFT collectibles categorized as the Premier drops and Signature drops within the Preseason Access Collection. These NFTs will be available for USD purchase at a range of prices with the goal of lowering the barriers to entry for fans who want to begin collecting NFTs while still appealing to seasoned collectors.

07:48 EDT Delta 9 Cannabis announces Health Canada approval for expansion - DELTA 9 CANNABIS announced that on August 6, 2021, the Company received approval from Health Canada for two expansion approvals for its Winnipeg based cultivation, processing, and distribution facilities. The Expansion Approval allows for; an expansion of the Company's licensed perimeter at its Winnipeg based facilities, expanding the area currently under license from approximately 80,000 square feet to approximately 95,000 square feet, and the licensing of a new 7,500 square foot purpose-built storage and distribution area. The expanded licensed perimeter will allow the Company to improve control systems within its licensed perimeter, improve the operational flow of its operations, and to position the Company to better plan for future expansions of the Company's licensed cannabis operations areas. The new purpose-built storage and distribution area will allow the Company to improve its product packaging, case-packing, and distribution efficiency to better allow it to cater to its provincial distribution markets across Canada. The Company anticipates that the new storage area will improve its value proposition in various provincial markets across the country.

07:46 EDT AzurRx adds five new clinical trial sites for Phase 2 RESEVOIR trial for FW-1022 - AzurRx BioPharma announced the completion of site initiation visits and the addition of five new clinical trial sites in Ukraine for the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. The RESERVOIR clinical trial is designed as a two-part, two-arm, placebo-controlled Phase 2 study. The trial's primary objectives are to confirm the safety of FW-1022 in the treatment of patients with COVID-19-related GI infections and to evaluate its efficacy in clearing SARS-CoV-2 from the GI tract. Topline data from the study is anticipated during the first quarter of 2022. "Niclosamide represents an important advance in the fight to help COVID-19 patients overcome the debilitating and often overlooked effect the virus can have on the GI system," said James Sapirstein, Chairman, CEO and President of AzurRx BioPharma. "While vaccines have been delivered to millions of people, COVID-19, and, in particular, the highly infectious Delta variant, remains a significant concern, especially in regions of the U.S. and areas of the world where vaccination rates are low. The addition of new trial sites in Ukraine provides enhanced opportunity to enroll patients in a country where less than 5% of the population is fully vaccinated for COVID-19."

07:45 EDT Archer Aviation hires Ben Lu as Chief Financial Officer - Archer Aviation announced the appointment of Ben Lu as the company's Chief Financial Officer. Ben will oversee the company's finances as Archer transitions to a public company following the completion of the proposed business combination with Atlas Crest Investment (ACIC), which is currently expected to close this fall. As CFO, Ben will continue to grow and oversee the finance and investor relations departments at Archer. As the company's first C-suite level finance hire, Ben is positioned at the helm of the company's emergence from private to public. In this role, he will leverage operational finance with a strategic mindset to maximize company value. In establishing this framework, Ben will work through the lens of an investor as the proposed business combination - announced in February - is finalized this fall. Ben arrives at Archer following a successful five-year period at Logitech (LOGI), where he was most recently the VP of Finance managing a global finance team, including Corporate FP&A, Treasury, Investor Relations and various other finance functions.

07:44 EDT Recro Pharma enters LOI for acquisition of CDMO - Recro Pharma announced that it has signed a non-binding letter of inten for its acquisition of a full service CDMO with capabilities that range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. Pursuant to the LOI, Recro agreed to acquire 100% of the equity interests of the Target in exchange for consideration having an aggregate value of approximately $49.850 million, assuming a cash free, debt free balance sheet and that the Target has, at closing, an adequate level of working capital to support the operations of its business post-closing. The purchase price will be paid through: $25.5 million of cash at closing; 9,302,718 shares of common stock of Recro to be issued to Target in six months; and seller notes of $6.1 million. The seller notes will have a three year maturity date from the date of closing and bear interest at a rate of 6% annually. The seller notes will be expressly subordinated and unsecured in right of payment and priority to Recro's existing debt with Athyrium Capital Management.

07:42 EDT Marimed adds Robert Hall, Kevin Compagna to executive team - MariMed announced a series of appointments intended to help the company drive sales of its brand portfolio. Senior CPG marketer and former Sam Adams beer Chief Marketing Officer, Robert Hall, has been appointed as a Senior Brand and Marketing Advisor to MariMed. In that capacity, he will help MariMed establish data-supported, distinct brand strategies and brand building techniques as the Company expands the distribution of its top selling brands and products across the country. Hall will also assist the Company in the expansion of its marketing team and organization. Kevin Compagna has joined MariMed as Vice President, Wholesale & Licensing for North America. The sales executive will be responsible for driving revenues and market share for the company's top-selling products, including Betty's Eddies fruit chews and Nature's Heritage high quality flower brand, in markets where MariMed is already licensed as well as new markets via licensing partnerships.

07:40 EDT Calibre Mining announces drill results from Eastern Borosi Project - Calibre Mining is pleased to provide drill results and an update on the progress at its 100% owned Eastern Borosi Project located in northeastern Nicaragua. Calibre is advancing the high-grade open pit, and underground resource veins at EBP to provide mill feed to the Libertad mill which has surplus capacity. A multi-rig resource expansion and discovery drilling program is now underway along strike of the known vein systems. Highlight Infill Drill Results: Guapinol Open Pit: 25.07 g/t Au over 9.7 metres ETW from 44.8 metres; 39.21 g/t Au over 3.1 metres ETW from 204.2 metres; 24.85 g/t Au over 3.9 metres ETW from 125.8 metres. Vancouver Open Pit: 9.38 g/t Au over 2.2 metres ETW from 134.5 metres in the HW vein and 8.90 g/t Au over 2.3 metres ETW from 150.0 metres in the FW vein; Riscos De Oro Underground: 33.64 g/t Au over 3.2 metres ETW from 311.8 metres; 1.26 g/t Au over 2.8 metres ETW from 306.0 metres. Darren Hall, President & Chief Executive Officer of Calibre, stated: "Today's infill drill results continue to demonstrate the high-grade nature of these deposits with Guapinol and Riscos de Oro delivering the best results to date. With EBP located within trucking distance of our Libertad mill, along established infrastructure, the project is poised to deliver our lowest cost ounces, again demonstrating the ability to efficiently translate satellite deposits into near term, high margin mill feed. The project is advancing ahead of our initial expectations with updated mineral resource estimates expected in Q1 2022 and operating permit submissions within the next six months. Furthermore, we see excellent exploration potential for discovering additional high-grade vein systems across the 176 km2 EBP land package. The exploration team have begun drilling high-priority targets for further resource expansion along the Guapinol and Riscos de Oro vein trends and for the discovery of new bonanza-style gold-silver vein systems along underexplored gold trends in the district."

07:38 EDT Decibel Therapeutics sees cash, cash equivalents funding operations into 2024 - Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its pipeline programs and operating expenses into 2024.

07:37 EDT MindMed adds Robert Dworkin to its Scientific Advisory Board - MindMed announces the addition of Robert H. Dworkin, to its Scientific Advisory Board. Dworkin has spent over 35 years conducting clinical research on pain. He is currently Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Professor in the Center for Health + Technology, at the University of Rochester School of Medicine and Dentistry. He holds additional roles as the Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks public-private partnership with the FDA; Special Government Employee of the FDA Center for Drug Evaluation and Research; and Associate Editor of Pain and a member of the Editorial Boards of Canadian Journal of Pain and Journal of Pain. Among his many awards, Dr. Dworkin received the American Pain Society's Wilbert E. Fordyce Clinical Investigator Award in 2005 and John and Emma Bonica Public Service Award in 2014, the American Academy of Neurology's Mitchell B. Max Award for Neuropathic Pain in 2015, and the International Association for the Study of Pain's John D. Loeser Award in 2020.

07:36 EDT Finch Therapeutics says Takeda to accelerate leadership role in FIN-524 program - Finch Therapeutics Group (FNCH) announced that Takeda Pharmaceutical Company Limited (TAK) has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program. Takeda will assume primary development responsibility for the program, now known as TAK-524, ahead of the planned initiation of clinical-stage development. The transition will enable Takeda to leverage its expertise in inflammatory bowel disease throughout the clinical development of FIN-524/TAK-524. FIN-524/TAK-524 is an investigational, orally administered targeted consortia product candidate composed of both spore-forming and non-spore-forming bacterial strains selected for the treatment of ulcerative colitis. FIN-524/TAK-524 is designed to treat ulcerative colitis by harnessing the gut microbiome's ability to modulate the host immune system.

07:35 EDT SciPlay forms special committee to review Scientific Games' proposal - SciPlay (SCPL) announced that its Board of Directors has formed a special committee of independent directors consisting of William Thompson, Gerald Cohen, and Michael Marchetti. The Board has granted the Special Committee independent authority to review and evaluate a previously announced proposal that the Board received on July 15 from Scientific Games (SGMS), proposing that Scientific Games acquire the remaining 19% equity interest in SciPlay that Scientific Games does not currently own in an all-stock transaction. In the Proposed Transaction, SciPlay shareholders, other than Scientific Games and its subsidiaries, would receive 0.250 shares of Scientific Games common stock for each share of SciPlay Class A common stock they own, which would imply a premium of 11% based on the Scientific Games and SciPlay respective stock prices as of the close of business on July 14, the last trading day prior to Scientific Games' proposal. The Special Committee has retained Lazard as its financial advisor and Sullivan & Cromwell LLP as its legal counsel in connection with its review and evaluation of the Proposed Transaction.

07:33 EDT Verrica Pharmaceuticals expects cash to support operations at least into 1Q23 - As of June 30, 2021, Verrica had aggregate cash, cash equivalents, and marketable securities of $90.1 million. The Company believes that its existing cash, cash equivalents, and marketable securities as of June 30, 2021 will be sufficient to support planned operations at least into the first quarter of 2023.

07:33 EDT NCR Corp. receives final CMA approval to combine with Cardtronics - NCR Corp. announced it has received final approval to combine with Cardtronics from the Competition and Markets Authority, or CMA, of the United Kingdom. The CMA approved the transaction without any conditions. All regulatory approvals and consents are now secured, and the transaction is complete.

07:30 EDT Kornit Digital acquires Voxel8, expanding technology portfolio - Kornit Digital announced the acquisition of all associated assets of Somerville, Massachusetts-based Voxel8. Voxel8's advanced additive manufacturing technology for textiles allows for digital fabrication of functional features with zonal control of material properties, in addition to utilizing high-performance elastomers adhering to inkjet technology. "By integrating Voxel8's technology into Kornit's product roadmap, we will be able to transform numerous market segments and verticals, accelerating our collective visions and technology advancements," said Kobi Mann, Kornit Digital Chief Technology Officer. "Voxel8 offers direct 3D print-on-part capabilities, advanced design software that can be easily integrated with any production floor software workflow, and versatile chemistry enabling on-the-fly formulation of high-performance elastomers to change the material properties of the resulting printed structures by multiple orders of magnitude. This means reflective, high-density, silicone and metallics, as well as compression elements for sports and therapeutics, protection elements like cushioning and impact resistance, and functionality applications like anti-slip, waterproofing, and other qualities combining form and function that are key to Kornit's vision of digitizing production in every conceivable manner."

07:23 EDT Fulcrum Therapeutics provides upcoming milestones - Fulcrum plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients with FTX-6058 in the fourth quarter of 2021. Fulcrum plans to submit an IND in non-sickle cell disease hemoglobinopathies by year-end 2021. Fulcrum plans to meet with health authorities, including the U.S. Food and Drug Administration, in the second half of 2021 to determine the regulatory path for losmapimod in FSHD.

07:21 EDT Flora Growth unit completes 1st order valued at $1.1M to Tropi - Flora Growth is pleased to announce that its food and beverage division, Kasa Wholefoods Company has completed its first purchase order, valued at approximately US$1.1M, to Importaciones y Asesorias ,Tropi, as part of the sales agreement announced in July. Flora expects Kasa to complete similar deliveries on a monthly basis moving forward. Kasa intends on leveraging this initial sales agreement with Colombia's largest consumer packaged goods, CPG, distributor to generate additional sales of its entire food and beverage product portfolio in Colombia. Given the recently announced cannabis law changes in Colombia that will allow for the production and marketing of cannabinoid-containing ingestible products, Kasa will look to maximize the value of the relationship and amplify revenue growth of its CBD product portfolio. This agreement exemplifies Flora Growth's strategy of building out its distribution channels and sales relationships utilizing high-quality traditional CPG products, underpinned by its low-cost, high-margin cannabis raw materials. "We believe this initial sale demonstrates Flora's ability to rapidly follow through on its commitments and marks a major turning point for our Kasa Wholefoods division. We expect this relationship with Tropi to generate significant revenue potential in both the short and long term as we build upon a relationship with the leading food and beverage distributor in Colombia," said Jason Warnock, Chief Revenue Officer of Flora. "Moving forward, we will work to increase monthly sales to our target of US$2M, including foraying into the newly permitted product category of cannabis-containing ingestible products that will offer increased wellness properties for end consumers."

07:19 EDT Lithia Motors reports 800 transaction in July up 45% from the previous quarter - Lithia & Driveway reported transaction volume acceleration and are exceeding mid-year projections. Driveway reported 800 transactions in the month of July, compared to 550 in June, a 45% increase month-over-month. The company is now pacing nearly 10,000 annual transactions and one large step closer to the year-end run rate target of 15,000.

07:18 EDT IMV Inc. announces final topline results from DeCidE1 - IMV Inc. announced the final topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S in subjects with advanced recurrent ovarian cancer. Secondary endpoints in the DeCidE1 clinical study included an extensive analysis of collected biological samples. Jeremy Graff, chief scientific officer of IMV commented, "The translational analyses provide strong evidence that maveropepimut-S successfully elicits the generation of tumor antigen-specific T cells. Importantly, these analyses affirm the molecular and cellular mechanism of MVP-S based therapy. This data will also inform the discussion and design of a Phase 2 clinical study to be submitted to the FDA." The details of these translational analyses have been submitted to upcoming scientific meetings for presentation.

07:16 EDT Aeva Technologies announces strategic LiDAR collaboration with Nikon - Aeva announced a strategic collaboration with Nikon, a manufacturer and supplier of metrology and inspection equipment for the industrial automation and metrology markets. The companies will focus on bringing Frequency Modulated Continuous Wave, or FMCW, 4D LiDAR with unique micron-level measurement capability to high precision industrial automation and metrology applications.

07:14 EDT CDW announces Al Miralles as CFO - CDW (CDW) announced that Al Miralles will join CDW as senior vice president and CFO, effective September 7. He will succeed Collin Kebo, who previously announced his intention to retire after 13 years with CDW. Miralles will report to Christine Leahy, president and chief executive officer. Miralles joins CDW from CNA Financial (CNA) where he most recently served as executive VP and CFO.

07:14 EDT BioXcel Therapeutics reviews upcoming milestones - For the company's neuroscience program: plans are underway for a Marketing Authorization Application with the European Medicines Agency of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I & II in 2H 2021. For the company's immuno-oncology program: data readout from the adenocarcinoma cohort of the Phase 1b/2 trial of BXCL701 and pembrolizumab in aggressive forms of prostate cancer is planned for Q3 2021.

07:13 EDT Canadian Pacific offer represents enterprise value of approximately $31B

07:12 EDT Cathie Wood's ARK Investment bought 316.8K shares of TuSimple on Monday

07:11 EDT BioXcel Therapeutics reports Q2 EPS ($1.11), consensus ($1.08) - In June 2021, the Company raised gross proceeds of approximately of $100M in a common stock offering, providing sufficient cash runway to further fund ongoing clinical development studies and commercialization readiness preparations. "During the second quarter, we continued to successfully execute across our clinical, regulatory and commercial objectives for our neuroscience candidate, BXCL501, including furthering our plans for the pivotal Phase 3 program in dementia, executing on our global expansion strategy, and advancing through the regulatory review process," said Vimal Mehta, Ph.D., CEO of BioXcel. "With acceptance of our NDA by the FDA, we are one step closer to our first-ever product approval and making this innovative therapy available to patients suffering from acute agitation associated with schizophrenia and bipolar disorders. We continue to advance our commercial readiness strategy, if approved, and in parallel are advancing our strategic plans for geographic expansion."

07:10 EDT Clene expects cash to fund expenses for a period extending beyond 12 months - Clene's cash totaled approximately $63.0 million as of June 30, 2021, compared to approximately $59.3 million as of December 31, 2020. The increase in cash through the second quarter ended June 30, 2021 was primarily due to approximately $17.7 million of net cash used in operating activities; $0.4 million of net cash used in investing activities; and $21.9 million of net cash provided by financing activities. Included in net cash provided by financing activities is $9.3 million of net proceeds from a PIPE offering and $14.5 million of net proceeds from a venture loan agreement which occurred concurrently in May 2021. Clene expects that its cash as of June 30, 2021 will be sufficient to fund its operations for a period extending beyond twelve months from the date the June 30, 2021 condensed consolidated financial statements are issued.

07:09 EDT Innoviz Technologies forms partnership with Curium - Innoviz Technologies has formed a partnership with Curium, a leading developer of automated calibration services for Autonomous Systems. Curium's automated calibration software ensures that the vehicle's sensor suite is working as it should, even under dynamically changing conditions. Through the partnership agreement, Curium will apply its patented calibration techniques to its advanced driving system using the advanced capabilities of Innoviz's solid-state LiDAR sensor. Curium's solution actually simplifies the integration of the InnovizOne Lidar into any vehicle, as well as the installation of the sensor in the production stage.

07:07 EDT Altair Engineering acquires S-FRAME Software - Altair announced that it has acquired S-FRAME Software, a structural analysis software platform used by engineers to evaluate a structure's ability to withstand external loads and meet design code requirements around the world. S-FRAME Software's integrated solutions make it possible to analyze, design, and detail structures regardless of geometric complexity, loading conditions, nonlinear effects, design code requirements, or material type including steel, concrete, composites, or mass timber, one of the hottest in sustainable building materials. S-FRAME Software will be available via Altair Units, Altair's patented, subscription-based licensing model, which allows organizations to pay only for what their employees need, when they need it.

07:05 EDT Sigilon Therapeutics announces anticipated milestones - Sigilon expects to initiate a Phase 1/2 trial of SIG-005 in patients with MPS-1 in the second half of 2021. The Company expects to disclose up to 9 months of follow-up data for three patients from the Phase 1/2 safety and dose-ranging study of SIG-001 in severe to moderate-severe hemophilia in the third quarter of 2021.

07:02 EDT Achilles Therapeutics expects cash to fund operations into 2H23 - Cash and cash equivalents were $299.3 million as of June 30, 2021, as compared to $177.8 million as of December 31, 2020. Current cash and cash equivalents include net proceeds of $160.6 million from an initial public offering that closed in the second quarter. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2023, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.

06:57 EDT Sonic Automotive opens new delivery center in the Austin market - Sonic Automotive announced the opening of its newest delivery center in the Austin market. This is the sixth EchoPark location in Texas.

06:43 EDT Merck: FDA grants priority review for new sBLA for Keytruda - Merck announced that the U.S. FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. This sBLA is based on data from the pivotal Phase 3 KEYNOTE-564 trial, in which KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in disease-free survival compared to placebo. These data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. The FDA has set a Prescription Drug User Fee Act, or target action, date of December 10, 2021.

06:37 EDT Graham promotes Daniel Thoren to CEO - Graham announced that its Board of Directors has appointed Daniel J. Thoren as its President and CEO, effective September 1. Thoren will also join the Board of Directors upon assuming the new role. Thoren currently serves as Graham's President and COO. He will succeed James Lines, who plans to retire from the Company and step down from the Board of Directors. Dan Thoren became Graham's President and COO in June. Prior to that, Thoren served as Barber Nichols' President and CEO since 1997 and more than quadrupled the size of the business in that time. From 1991 to 1997, he held Senior Engineer and Engineering management posts at the company. Thoren earned a B.S. degree in Mechanical Engineering from the University of Wyoming and a M.S. degree in Organizational Management from the University of Colorado, Denver.

06:12 EDT Nielsen, Meredith reach multi-year renewal agreement for local TV ratings - Nielsen (NLSN) and Meredith (MDP) announced that they have reached a multi-year renewal agreement for Nielsen Local TV ratings. The agreement includes a range of audience measurement and analytical services across all Meredith's local stations, including Nielsen Scarborough. Nielsen Scarborough will provide consumer behavior data on more than 2,000 categories about local shopping, product purchasing, lifestyle and media usage to give Meredith a view of the local market consumer.

06:10 EDT Genasys awarded five-year public safety alert software services contract - Genasys announced a five-year public safety alert software services contract from the municipality of Longueuil, Montreal's second largest suburb and the fifth largest city in Quebec.

06:04 EDT Equifax to acquire Appriss Insights for $1.83B, sees EPS accretion in 2022 - Equifax has signed a definitive agreement to acquire Appriss Insights, a source of risk and criminal justice intelligence, for $1.83B. In conjunction with the acquisition, Equifax will receive a tax benefit with a net present value at time of purchase of approximately $360M. Appriss Insights, a portfolio company of Clearlake Capital and Insight Partners, provides data used in public and workplace safety, law enforcement, fraud detection and prevention, and healthcare credentialing. Appriss Insights is expected to generate approximately $150M of revenue in 2021, up 30% over last year, and the transaction is expected to be accretive to Equifax adjusted EPS in 2022. Appriss Insights was founded in 1994 with the creation of the VINEnetwork, a proprietary victim notification network that empowers victims with information regarding incarcerated persons. VINE uses Appriss' incarceration data network to deliver more than 25M notifications every year and is utilized by 47 states and the territory of Guam to protect crime victims. Appriss Insights' incarceration data network has more than 170M historical booking records accounting for over 90% of near real-time incarcerations in the United States. The company also has built a proprietary national criminal justice database, NCIS. Appriss Insights will continue to be led by Brian Matthews and will be based in Louisville, Kentucky. Its employees will join the Equifax workforce solutions business. Appriss Health and Appriss Retail will remain part of Appriss Inc. and are not a part of this transaction. The transaction is subject to customary closing conditions and regulatory review and is expected to close in the second half of 2021.

05:42 EDT Osisko Gold increases quarterly dividend 10% - Osisko Gold announced a Q3 dividend of C$0.05.5 per common share, a 10% increase over Q2, for an annualized dividend of 22c per share. The dividend will be payable on October 15 to shareholders of record as of the close of business on September 30.

05:21 EDT ASE Technology reports July revenue $1.67B vs. $1.26B last year, up 32.1%

05:15 EDT ChipMOS reports July revenue $86.5M, up 28.2% - The company said its assembly and DDIC high-end test platforms remain at high utilization levels, with continued strong demand across its businesses driving the record monthly revenue.

05:04 EDT Google Cloud, Workday announce multi-year strategic partnership - Google Cloud (GOOG) and Workday (WDAY) announced a strategic partnership. As a Workday preferred cloud partner across industries-such as healthcare, financial services, and retail-Google Cloud will help businesses run Workday enterprise applications for finance, HR, and planning in a public cloud environment. This includes providing cloud solutions that give employees secure access to applications and data. The strategic relationship announced between Workday and Google Cloud will provide customers with greater choice to meet their specific business needs. Customers will be able to deploy Workday Financial Management, Workday Human Capital Management and Workday Adaptive Planning all on Google Cloud's infrastructure. Through this multi-year relationship, Google Cloud and Workday plan to build strategic, joint, go-to-market programs that include co-marketing activities and establishing co-selling programs to increase awareness among customers and prospects across the U.S.. Additionally, the two companies will explore opportunities for co-innovation.